InvestorsHub Logo
Followers 8
Posts 329
Boards Moderated 0
Alias Born 01/12/2012

Re: eicoman post# 4435

Thursday, 06/21/2012 2:11:07 AM

Thursday, June 21, 2012 2:11:07 AM

Post# of 30393
Thanks for the Info, Eicoman..

Wow.. Just Finished Listening to the Recorded Conference Call..

A few things to think About..

Very Nice Fit- We get a Company that is Profitable ( As is, No Cash Burn )..

We pay with Shares- That by the way.. Are in someway RESTRICTED, as they ( Finesco / Scomedica ) cannot sell more than 5% of the Total Volume traded a DAY BEFORE..! In other words.. Take Today for Example.. 214,000 Shares Traded. ( that would mean they could only SELL 10,500 shares of Apricus Tomorrow, if that would be what they wanted to do..! )
15% of their Total Shares are Delivered to an Agent and Kept in Escrow for 1 Year..!

We get Access to the Biggest Alprostadil Market in Europe..! We sell our OWN Products and Keep the Profits..

Access to a $22M -$23 M USD per Year Injectable Alprostadil Market, which makes them PERFECT Candidates to Win the Users Over to a Topical Alprostadil Delivery ( Vitaros )..

I Agree With Dimitrios' Assesment.. IT's a Game Changer..!

I especially like the "RESTRICTED" clause on the Shares that will be Given to them ..!

http://www.sec.gov/Archives/edgar/data/1017491/000114420412035589/v316482_8k.htm

"As a condition to closing, the Company and Sellers have agreed to enter into a Registration Rights and Transfer Restriction Agreement, pursuant to which, among other things, the Shareholders would be restricted from selling on any given day more than five percent (5%) of the prior day’s total share trading volume as reported on the NASDAQ Capital Market."



Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent SEEL News